78
/ 100
Mostly True
United States
The text discusses findings on GLP-1 receptor agonists, including no causal link to suicidal ideation, reduced risks of suicidal behavior, and potential psychiatric effects in certain populations.
Infact verdict: Mostly True (78/100).
The claims regarding GLP-1 receptor agonists and their effects on mental health have been evaluated based on available evidence. The U.S. FDA and the European Medicines Agency have found no causal link between GLP-1 receptor agonists and suicidal ideation, which is supported by multiple sources. Reanalyses of the STEP trials confirm that semaglutide does not increase depressive symptoms or suicidality compared to placebo. Observational studies suggest a protective effect of GLP-1 RAs against suicidal behaviors. However, some studies indicate increased risks of depression and anxiety in specific populations, such as obese patients. Overall, the evidence supports the claims with varying degrees of certainty, reflecting the complexity of the topic.
How is this score determined? →Individual claims
93
True
Health
The U.S. FDA and the European Medicines Agency found no causal association between GLP-1 receptor agonists and suicidal ideation.
The U.S. FDA and the European Medicines Agency have both concluded that there is no causal association between GLP-1 receptor agonists and suicidal ideation. This is supported by multiple sources, including The Pharmaceutical Journal and The Cardiology Advisor.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
40
Source Quality Score
85
Source Quality Weight
20
Llm Reasoning Score
90
Llm Reasoning Weight
40
Llm Reasoning Score Raw
90
Weighted Total
93
Evidence Summary
Multiple sources confirm no causal link between GLP-1 RAs and suicidal ideation.
90
True
Health
STEP 1–5 trial reanalyses confirmed semaglutide does not increase depressive symptoms or suicidality compared to placebo.
Reanalyses of the STEP trials indicate that semaglutide does not increase depressive symptoms or suicidality compared to placebo. This is supported by studies from PubMed and Penn Medicine.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
85
Web Consensus Weight
40
Source Quality Score
80
Source Quality Weight
20
Llm Reasoning Score
85
Llm Reasoning Weight
40
Llm Reasoning Score Raw
85
Weighted Total
90
Evidence Summary
STEP trials show no increase in depressive symptoms or suicidality with semaglutide.
70
Mostly True
Health
Large-scale observational studies link GLP-1 RAs to neutral or 40% to 73% lower risks of suicidal ideation and attempts compared to non-GLP-1 control regimens.
Observational studies suggest that GLP-1 RAs are associated with a lower risk of suicidal ideation and attempts compared to non-GLP-1 regimens. This is supported by studies from Wiley and PubMed.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
75
Web Consensus Weight
40
Source Quality Score
70
Source Quality Weight
20
Llm Reasoning Score
75
Llm Reasoning Weight
40
Llm Reasoning Score Raw
75
Weighted Total
70
Evidence Summary
Observational studies indicate a protective effect of GLP-1 RAs against suicidal behaviors.
88
True
Health
Pharmacovigilance data reveal disproportionate reporting for suicidal ideation in patients taking antidepressants or benzodiazepines.
Pharmacovigilance data show disproportionate reporting of suicidal ideation for patients on antidepressants and benzodiazepines. This is supported by studies from JAMA Network and Springer Nature.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
80
Web Consensus Weight
40
Source Quality Score
75
Source Quality Weight
20
Llm Reasoning Score
80
Llm Reasoning Weight
40
Llm Reasoning Score Raw
80
Weighted Total
88
Evidence Summary
Pharmacovigilance data show increased reporting of suicidal ideation for antidepressants and benzodiazepines.
59
Mixed
Health
A matched cohort study identified elevated hazard ratios for major depressive disorder, anxiety, and suicidal behavior among obese patients on GLP-1 RAs.
A matched cohort study indicates elevated risks of depression, anxiety, and suicidal behavior in obese patients on GLP-1 RAs. This is supported by studies from Nature and Obesity Medicine Association.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
60
Web Consensus Weight
40
Source Quality Score
65
Source Quality Weight
20
Llm Reasoning Score
60
Llm Reasoning Weight
40
Llm Reasoning Score Raw
60
Weighted Total
59
Evidence Summary
Studies show increased risks of depression and anxiety in obese patients on GLP-1 RAs.
67
Mostly True
Health
GLP-1 receptors dampen mesolimbic dopamine release, which can induce anhedonia and emotional flattening.
GLP-1 receptors are known to dampen mesolimbic dopamine release, potentially causing anhedonia and emotional flattening. This is supported by sources from Stanford and PillSorted.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
70
Web Consensus Weight
40
Source Quality Score
70
Source Quality Weight
20
Llm Reasoning Score
70
Llm Reasoning Weight
40
Llm Reasoning Score Raw
70
Weighted Total
67
Evidence Summary
GLP-1 receptors affect dopamine release, potentially causing anhedonia.
